Patents by Inventor Xingye Ren
Xingye Ren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12129266Abstract: The present disclosure provides a substituted pyrazolo[1,5-a]pyridine compound, a composition including the same, and a use thereof. The substituted pyrazolo[1,5-a]pyridine compounds is a compound represented by formula (I) or the tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof. The compound of the present disclosure and composition thereof are useful for treating RET kinase-mediated diseases or conditions and have more excellent pharmacokinetic properties.Type: GrantFiled: December 3, 2019Date of Patent: October 29, 2024Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Publication number: 20240308987Abstract: A small molecule inhibitor targeting EB virus antigen protein, and/or a pharmaceutical composition comprising same, capable of being used for treating diseases caused by EB virus infection, such as, but not limited to, cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis, especially nasopharyngeal carcinoma. The present disclosure further provides a small molecule inhibitor against nasopharyngeal carcinoma, and/or a pharmaceutical composition comprising same, capable of being used for treating nasopharyngeal carcinoma.Type: ApplicationFiled: May 15, 2024Publication date: September 19, 2024Inventors: Zhendong ZHU, Zhengshuang XU, Ting LI, Chao CHE, Xingye REN, Sigui CHEN, Jiayin ZHANG, Ben ZHANG, Qi YANG, Chuanbing ZHANG, Zhen YANG
-
Patent number: 11802113Abstract: The present invention provides substituted pyrazole compounds, compositions containing same, and use thereof. The substituted pyrazole compounds comprise a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate, or solvate thereof. The compound represented by formula (I) can serve as a tissue selective androgen receptor modulator (SARM), particularly serving as a drug for treating prostate cancer and other AR-dependent conditions and diseases in which AR antagonism is desired.Type: GrantFiled: February 26, 2020Date of Patent: October 31, 2023Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Publication number: 20220251046Abstract: The present invention provides substituted pyrazole compounds, compositions containing same, and use thereof. The substituted pyrazole compounds comprise a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystalline form, pharmaceutically acceptable salt, hydrate, or solvate thereof. The compound represented by formula (I) can serve as a tissue selective androgen receptor modulator (SARM), particularly serving as a drug for treating prostate cancer and other AR-dependent conditions and diseases in which AR antagonism is desired.Type: ApplicationFiled: February 26, 2020Publication date: August 11, 2022Inventors: Yihan WANG, Xingye REN
-
Publication number: 20220017539Abstract: The present disclosure provides a substituted pyrazolo[1,5-a]pyridine compound, a composition including the same, and a use thereof. The substituted pyrazolo[1,5-a]pyridine compounds is a compound represented by formula (I) or the tautomers, stereoisomers, prodrugs, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereof. The compound of the present disclosure and composition thereof are useful for treating RET kinase-mediated diseases or conditions and have more excellent pharmacokinetic properties.Type: ApplicationFiled: December 3, 2019Publication date: January 20, 2022Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Publication number: 20210386737Abstract: A dihydroimidazopyrazinone compound, a composition including the same, and a use thereof. The dihydroimidazopyrazinone compound is a compound represented by formula (I) or a tautomer, stereoisomer, prodrug, crystal form, pharmaceutically acceptable salt, hydrate, or solvate thereof. The compound and the composition thereof can be used to treat a proliferative disease regulated by RAS/RAF/MEK/ERK kinase and have excellent pharmacokinetic properties.Type: ApplicationFiled: September 30, 2019Publication date: December 16, 2021Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Patent number: 11111233Abstract: An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.Type: GrantFiled: January 24, 2019Date of Patent: September 7, 2021Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren, Jian Jin, Huanyin Li, Yixin Ai
-
Patent number: 10851062Abstract: Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The substituted heteroaryl compound and the composition containing same set forth in the present invention can be used for regulating hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), simultaneously having better pharmacokinetic parameter characteristics and being able to improve the drug concentration of the compound in animal bodies, in order to improve the curative effect and safety of the drug.Type: GrantFiled: November 18, 2019Date of Patent: December 1, 2020Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Publication number: 20200190036Abstract: Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The substituted heteroaryl compound and the composition containing same set forth in the present invention can be used for regulating hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), simultaneously having better pharmacokinetic parameter characteristics and being able to improve the drug concentration of the compound in animal bodies, in order to improve the curative effect and safety of the drug.Type: ApplicationFiled: November 18, 2019Publication date: June 18, 2020Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Patent number: 10519193Abstract: Disclosed are a steroidal compound as shown in formula (I) and a drug composition containing the same, or a crystal form, a pharmaceutically acceptable salt, a hydrate or solvate, a stereoisomer, a prodrug, a metabolite or an isotopic variant thereof. The compound can be used as a CYP17 enzyme inhibitor, and has better pharmacokinetic parameters, which can improve drug concentration of the compound in an animal, thereby improving the efficacy and safety of the drug, and in turn the compound may be applied in the preparation of the drug for treating CYP17 enzyme-related diseases (such as prostate cancer).Type: GrantFiled: December 29, 2016Date of Patent: December 31, 2019Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Patent number: 10479767Abstract: Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The substituted heteroaryl compound and the composition containing same set forth in the present invention can be used for regulating hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), simultaneously having better pharmacokinetic parameter characteristics and being able to improve the drug concentration of the compound in animal bodies, in order to improve the curative effect and safety of the drug.Type: GrantFiled: December 13, 2016Date of Patent: November 19, 2019Assignee: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Publication number: 20190152954Abstract: An amino pyrimidine compound for inhibiting protein tyrosine kinase activity, a pharmaceutical composition thereof, preparation therefor, and an application thereof. Specifically, an amino pyrimidine compound represented by formula (I), R1, R2, L, Y, R6, W, A, m, and n being defined in the specification, and a pharmaceutically acceptable salt, a stereoisomer, a solvent compound, a hydrate, a polymorphism, a prodrug, or an isotope variant thereof. The compound can be used for treating and/or preventing protein tyrosine kinase-related diseases such as cell proliferative diseases, cancers, and immune diseases.Type: ApplicationFiled: January 24, 2019Publication date: May 23, 2019Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren, Jian Jin, Huanyin Li, Yixin Ai
-
Publication number: 20190092733Abstract: Provided in the present invention are a substituted heteroaryl compound, a composition containing same, and an application thereof, the present invention disclosing a heteroaryl compound of the formula (I), or a crystalline form, a pharmaceutically acceptable salt, a prodrug, a stereoisomer, a hydrate, or a solvent compound thereof. The substituted heteroaryl compound and the composition containing same set forth in the present invention can be used for regulating hypoxia inducible factor (HIF) and/or endogenous erythropoietin (EPO), simultaneously having better pharmacokinetic parameter characteristics and being able to improve the drug concentration of the compound in animal bodies, in order to improve the curative effect and safety of the drug.Type: ApplicationFiled: December 13, 2016Publication date: March 28, 2019Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren
-
Publication number: 20190040098Abstract: Disclosed are a steroidal compound as shown in formula (I) and a drug composition containing the same, or a crystal form, a pharmaceutically acceptable salt, a hydrate or solvate, a stereoisomer, a prodrug, a metabolite or an isotopic variant thereof. The compound can be used as a CYP17 enzyme inhibitor, and has better pharmacokinetic parameters, which can improve drug concentration of the compound in an animal, thereby improving the efficacy and safety of the drug, and in turn the compound may be applied in the preparation of the drug for treating CYP17 enzyme-related diseases (such as prostate cancer).Type: ApplicationFiled: December 29, 2016Publication date: February 7, 2019Applicant: Shenzhen TargetRx, Inc.Inventors: Yihan Wang, Xingye Ren